Literature DB >> 22158616

Identification of functionally distinct TRAF proinflammatory and phosphatidylinositol 3-kinase/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (PI3K/MEK) transforming activities emanating from RET/PTC fusion oncoprotein.

Josephine H F Wixted1, Jay L Rothstein, Laurence C Eisenlohr.   

Abstract

Thyroid carcinomas that harbor RET/PTC oncogenes are well differentiated, relatively benign neoplasms compared with those expressing oncogenic RAS or BRAF mutations despite signaling through shared transforming pathways. A distinction, however, is that RET/PTCs induce immunostimulatory programs, suggesting that, in the case of this tumor type, the additional pro-inflammatory pathway reduces aggressiveness. Here, we demonstrate that pro-inflammatory programs are selectively activated by TRAF2 and TRAF6 association with RET/PTC oncoproteins. Eliminating this mechanism reduces pro-inflammatory cytokine production without decreasing transformation efficiency. Conversely, ablating MEK/ERK or PI3K/AKT signaling eliminates transformation but not pro-inflammatory cytokine secretion. Functional uncoupling of the two pathways demonstrates that intrinsic pro-inflammatory pathways are not required for cellular transformation and suggests a need for further investigation into the role inflammation plays in thyroid tumor progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22158616      PMCID: PMC3281745          DOI: 10.1074/jbc.M111.322677

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  80 in total

1.  The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.

Authors:  Rosa Marina Melillo; Maria Domenica Castellone; Valentina Guarino; Valentina De Falco; Anna Maria Cirafici; Giuliana Salvatore; Fiorina Caiazzo; Fulvio Basolo; Riccardo Giannini; Mogens Kruhoffer; Torben Orntoft; Alfredo Fusco; Massimo Santoro
Journal:  J Clin Invest       Date:  2005-03-10       Impact factor: 14.808

2.  Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.

Authors:  Maria Grazia Borrello; Luisella Alberti; Andrew Fischer; Debora Degl'innocenti; Cristina Ferrario; Manuela Gariboldi; Federica Marchesi; Paola Allavena; Angela Greco; Paola Collini; Silvana Pilotti; Giuliana Cassinelli; Paola Bressan; Laura Fugazzola; Alberto Mantovani; Marco A Pierotti
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

3.  RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response.

Authors:  E Puxeddu; J A Knauf; M A Sartor; N Mitsutake; E P Smith; M Medvedovic; C R Tomlinson; S Moretti; J A Fagin
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

Review 4.  Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics.

Authors:  Cornelia M Ulrich; Jeannette Bigler; John D Potter
Journal:  Nat Rev Cancer       Date:  2006-02       Impact factor: 60.716

5.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

6.  RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.

Authors:  Kerry J Rhoden; Kristian Unger; Giuliana Salvatore; Yesim Yilmaz; Volodymyr Vovk; Gennaro Chiappetta; Mazin B Qumsiyeh; Jay L Rothstein; Alfredo Fusco; Massimo Santoro; Horst Zitzelsberger; Giovanni Tallini
Journal:  J Clin Endocrinol Metab       Date:  2006-04-04       Impact factor: 5.958

7.  Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation.

Authors:  Christy M Caudill; Zhaowen Zhu; Raffaele Ciampi; James R Stringer; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2005-01-25       Impact factor: 5.958

Review 8.  RET tyrosine kinase signaling in development and cancer.

Authors:  Elena Arighi; Maria Grazia Borrello; Hannu Sariola
Journal:  Cytokine Growth Factor Rev       Date:  2005 Aug-Oct       Impact factor: 7.638

9.  Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene.

Authors:  Carlo Iavarone; Mario Acunzo; Francesca Carlomagno; Annunziata Catania; Rosa M Melillo; Stella M Carlomagno; Massimo Santoro; Mario Chiariello
Journal:  J Biol Chem       Date:  2006-02-16       Impact factor: 5.157

10.  Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.

Authors:  Bin Ouyang; Jeffrey A Knauf; Eric P Smith; Lei Zhang; Tim Ramsey; Naeem Yusuff; David Batt; James A Fagin
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

View more
  8 in total

1.  Effect of TRAF6 on the biological behavior of human lung adenocarcinoma cell.

Authors:  Lou Zhong; Fei Cao; Qingsheng You
Journal:  Tumour Biol       Date:  2012-10-04

2.  Proteomic and clinical biomarkers for acute mountain sickness in a longitudinal cohort.

Authors:  Jing Yang; Zhilong Jia; Xinyu Song; Jinlong Shi; Xiaoreng Wang; Xiaojing Zhao; Kunlun He
Journal:  Commun Biol       Date:  2022-06-06

3.  TRAF6 regulates proliferation, apoptosis, and invasion of osteosarcoma cell.

Authors:  Qingbing Meng; Minqian Zheng; Hongbing Liu; Changzhi Song; Wensheng Zhang; Juan Yan; Ling Qin; Xiaolan Liu
Journal:  Mol Cell Biochem       Date:  2012-08-12       Impact factor: 3.396

4.  Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma.

Authors:  Elisa Menicali; Sonia Moretti; Pasquale Voce; Serena Romagnoli; Nicola Avenia; Efisio Puxeddu
Journal:  Front Endocrinol (Lausanne)       Date:  2012-05-22       Impact factor: 5.555

5.  miRNA-200c inhibits invasion and metastasis of human non-small cell lung cancer by directly targeting ubiquitin specific peptidase 25.

Authors:  Jing Li; Qiang Tan; Mingxia Yan; Lei Liu; Hechun Lin; Fangyu Zhao; Guoliang Bao; Hanwei Kong; Chao Ge; Fanglin Zhang; Tao Yu; Jinjun Li; Xianghuo He; Ming Yao
Journal:  Mol Cancer       Date:  2014-07-06       Impact factor: 27.401

6.  Exploring the Mechanism of Baicalin Intervention in Breast Cancer Based on MicroRNA Microarrays and Bioinformatics Strategies.

Authors:  Anqi Ge; Lifang Liu; Xian'guang Deng; Jun Luo; Yanghua Xu
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-20       Impact factor: 2.629

Review 7.  TNF Receptor Associated Factor 2 (TRAF2) Signaling in Cancer.

Authors:  Daniela Siegmund; Jennifer Wagner; Harald Wajant
Journal:  Cancers (Basel)       Date:  2022-08-22       Impact factor: 6.575

8.  Up-regulation and pre-activation of TRAF3 and TRAF5 in inflammatory bowel disease.

Authors:  Jun Shen; Yu-qi Qiao; Zhi-hua Ran; Tian-rong Wang
Journal:  Int J Med Sci       Date:  2013-01-03       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.